Merck (MRK)

Add a New Bears Reason Company: Merck (MRK) Current price: Headline: (100 character max) Analysis: Cancel 68% agree 106 votes   Drug development is costly and its success is inherently risky Top Contributor: Kryssia Uraguchi | Created when NYSE:MRK was $50.23 | Edit | History Drug development is costly and its success is inherently uncertain. A candidate drug failing a late clinical trail would have significant financial consequences for the company. (100 character max) Cancel 0% agree 2 votes   Bad Stock to own Created when NYSE:MRK was $32.41 | Edit | History I believe the company is foundering and its in a panic mode. (100 character max) Cancel 12% agree 8 votes   Large Debt Load with S/P Acq. Created when NYSE:MRK was $29.78 | Edit | History See projected debt load and interest expense associated with Schering Plough acquisition. Totally changes financial profile. (100 character max) Cancel 31% agree 16 votes   The aftermath of Vioxx looks bleak Top Contributor: Kryssia Uraguchi | Created when NYSE:MRK was $50.23 | Edit | History As the Vioxx lawsuit continues to be played out, negative headlines and cash outflows will be a long-term concern for the company. Litigation is an ongoing concern for pharmaceutical giants. (100 character max) Cancel 29% agree 17 votes   Patent expirations and generic competition is bad for revenues Top Contributor: Kryssia Uraguchi | Created when NYSE:MRK was $50.23 | Edit | History 30% of sales through 2008 may be affected by generics due to patent expirations. (100 character max) Cancel

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.